Search

Paul M Sondel

from Madison, WI
Get Report
Related to:
Sherie A Sondel, 70Elana R Sondel, 40Peter C Bloch, 79Jodi Z Sondel, 35George Dellal, 41Marianne N Bloch, 77
Connected to:
Brianna M Sondenaa, 35Mark S Sonderby, 62Terry R Sonder, 40Brian M Sondergeld, 56Carolyn T Sonderer, 60Dana L Sondergaard, 33Doris U Sonderegger, 57Elaine L Sonderegger, 78Erol D Sonderegger, 50

Paul Sondel Phones & Addresses

  • 1675 Highland Ave, Madison, WI 53701 (608) 263-6420
  • 600 Highland Ave, Madison, WI 53792 (608) 263-6420
  • 1114 Winston Dr, Madison, WI 53711 (608) 271-8108

Work

Company: UW Health Pediatric Spclty Clnc Address: 1675 Highland Ave, Madison, WI 53792 Phones: (608) 263-6420

Education

School / High School: Harvard Medical School 1977

Languages

English • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatrics, 1981

Specialities

Pediatrics

Professional Records

Medicine Doctors

Paul Sondel Photo 1

Dr. Paul M Sondel, Madison WI - MD (Doctor of Medicine)

View page
Specialties:
Pediatrics
Address:
UW Health Pediatric Spclty Clnc
1675 Highland Ave, Madison, WI 53792
(608) 263-6420 (Phone)

600 Highland Ave, Madison, WI 53792
(608) 263-6420 (Phone), (608) 263-0440 (Fax)
Certifications:
Pediatrics, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Spanish
Hospitals:
UW Health Pediatric Spclty Clnc
1675 Highland Ave, Madison, WI 53792

600 Highland Ave, Madison, WI 53792

Meriter Hospital
202 South Parks Street, Madison, WI 53715

University of Wisconsin Hospitals And Clinics
600 Highland Avenue, Madison, WI 53792
Education:
Medical School
Harvard Medical School
Graduated: 1977
Medical School
University Minn Hosps
Graduated: 1978
Medical School
University Wisc Hospital
Graduated: 1980
Medical School
University Of Wisconsin Madison
Graduated: 1975
Paul Sondel Photo 2

Paul M. Sondel

View page
Specialties:
Pediatric Hematology-Oncology
Work:
UW Health ClinicsPediatric Specialty Clinic
1675 Highland Ave, Madison, WI 53792
(608) 263-6420 (phone), (608) 263-0440 (fax)
Education:
Medical School
Harvard Medical School
Graduated: 1977
Procedures:
Lumbar Puncture
Conditions:
Hemolytic Anemia
Leukemia
Languages:
English
Description:
Dr. Sondel graduated from the Harvard Medical School in 1977. He works in Madison, WI and specializes in Pediatric Hematology-Oncology. Dr. Sondel is affiliated with Meriter-UnityPoint Health Hospital and University Of Wisconsin Hospital.
Paul Sondel Photo 3

Paul M Sondel, Madison WI

View page
Specialties:
Pediatrics
Pediatric Hematology-Oncology
Public Health & General Preventive Medicine
Work:
University of Wisconsin at Madison
600 Highland Ave, Madison, WI 53792
Education:
Harvard University(1977)

Resumes

Resumes

Paul Sondel Photo 4

Paul Sondel

View page
Paul Sondel Photo 5

Professor At Uw-Madison School Of Medicine

View page
Position:
Professor at UW-Madison School of medicine
Location:
Madison, Wisconsin Area
Industry:
Medical Practice
Work:
UW-Madison School of medicine
Professor

Business Records

Name / Title
Company / Classification
Phones & Addresses
Paul Mark Sondel
Paul Sondel MD,PHD
Oncology · Pediatric Oncologist · Pediatrician
600 Highland Ave, Madison, WI 53792
(608) 263-6420
Paul M. Sondel
Medical Director
U of Wisconsin
Medical Doctor's Office
1111 Highland Ave, Madison, WI 53705

Publications

Us Patents

Method Of Culturing Lymphocytes And Method Of Treatment Using Such Lymphocytes

View page
US Patent:
54439833, Aug 22, 1995
Filed:
Mar 21, 1988
Appl. No.:
7/170755
Inventors:
Augusto C. Ochoa - St. Paul MN
Fritz H. Bach - Minneapolis MN
Barbara Alter - Marine on St. Croix MN
Paul Sondel - Madison WI
Assignee:
Regents of the University of Minnesota - Minneapolis MN
International Classification:
C12N 502
C12N 508
US Classification:
4352402
Abstract:
In accordance with the present invention, a method of culturing lymphocytes is disclosed in which the lymphocytes are cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an antibody to a lymphocyte T3 surface receptor. Preferably, the antibody is monoclonal. Cells cultured with anti-CD3 maintain their LAK activity as they increase in number. The cells can also be cultured in the presence of an additional lymphokine to obtain additional LAK activity. Methods of medical treatment are also disclosed in which cells cultured in accordance with the culturing methods of the present invention are introduced into the individual to be treated.

Method For Typing Human Leukocyte Antigens

View page
US Patent:
42658730, May 5, 1981
Filed:
Jul 3, 1978
Appl. No.:
5/921487
Inventors:
Michael J. Sheehy - Madison WI
Paul M. Sondel - Boston MA
Fritz H. Bach - Madison WI
Marilyn L. Bach - Madison WI
Rudolf Wank - New York NY
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
G01N 3316
A61K 4300
US Classification:
424 1
Abstract:
A cellular method for typing lymphocyte defined human leukocyte antigens by utilizing human blood leukocytes which have been sensitized to proliferatively respond to the secondary stimulus of the leukocyte antigens to which they have been sensitized. The sensitization is accomplished by incubating, in vitro, in a mixed leukocyte culture, the leukocytes to be sensitized with leukocytes differing by only a single major histocompatibility complex haplotype or a single HLA-D antigenic determinant.

Radiohalogenated Agents For In Situ Immune Modulated Cancer Vaccination

View page
US Patent:
20200330567, Oct 22, 2020
Filed:
Jul 2, 2020
Appl. No.:
16/919191
Inventors:
- Madison WI, US
Paul M. Sondel - Madison WI, US
Anatoly Pinchuk - Fitchburg WI, US
Zachary Morris - Madison WI, US
Mario Otto - Fitchburg WI, US
Bryan Bednarz - Madison WI, US
International Classification:
A61K 39/00
A61K 39/395
A61K 39/39
A61K 51/04
Abstract:
A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula:wherein Ris a radioactive halogen isotope, n is 18 and Ris —N(CH).

Targeted Radiotherapy Chelates For In Situ Immune Modulated Cancer Vaccination

View page
US Patent:
20200330621, Oct 22, 2020
Filed:
Jun 29, 2020
Appl. No.:
16/914563
Inventors:
- Madison WI, US
Paul Sondel - Madison WI, US
Anatoly Pinchuk - Fitchburg WI, US
Zachary Morris - Madison WI, US
Mario Otto - Fitchburg WI, US
Bryan Bednarz - Madison WI, US
Peter Carlson - Madison WI, US
International Classification:
A61K 51/04
A61K 39/395
A61K 9/00
A61K 38/20
C07K 16/30
Abstract:
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula:wherein Rcomprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and Ris —N(CH).

Bacterial Membrane Nanoparticles As An Immunotherapy System For Cancer Treatment

View page
US Patent:
20200078312, Mar 12, 2020
Filed:
Sep 5, 2019
Appl. No.:
16/562133
Inventors:
- Madison WI, US
Zachary Scott Morris - Madison WI, US
Mingzhou Ye - Madison WI, US
Ravi Bhasker Patel - Madison WI, US
Paul M. Sondel - Madison WI, US
International Classification:
A61K 9/50
A61P 35/00
A61K 39/39
A61K 9/51
Abstract:
Provided herein are nanoparticles comprising a polyplex core comprising one or more pH-responsive polymers and one or more anionic immune adjuvants, wherein each pH-responsive polymer comprises ionizable amine groups; and a shell of bacterial cell membrane components at least partially coating the polyplex core, wherein the bacterial cell membrane components comprise TLR 2 and/or TLR 4 agonists. Also provided are methods of stimulating an immune response in a mammal using the nanoparticle.

Using Targeted Radiotherapy (Trt) To Drive Anti-Tumor Immune Response To Immunotherapies

View page
US Patent:
20180126012, May 10, 2018
Filed:
Nov 10, 2017
Appl. No.:
15/809427
Inventors:
- Madison WI, US
Paul Sondel - Madison WI, US
Ravi Patel - Madison WI, US
Zachary Morris - Madison WI, US
Peter Carlson - Madison WI, US
Reinier Hernandez - Madison WI, US
Joseph Grudzinski - Madison WI, US
International Classification:
A61K 51/04
A61P 35/00
A61K 41/00
A61K 51/10
A61K 9/00
A61P 35/04
A61K 38/20
A61K 39/395
Abstract:
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein Rcomprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein Rcomprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and Ris —N(CH).

Targeted Radiotherapy Chelates For In Situ Immune Modulated Cancer Vaccination

View page
US Patent:
20180021461, Jan 25, 2018
Filed:
Jul 25, 2017
Appl. No.:
15/658535
Inventors:
- Madison WI, US
Paul Sondel - Madison WI, US
Anatoly Pinchuk - Fitchburg WI, US
Zachary Morris - Madison WI, US
Mario Otto - Fitchburg WI, US
Bryan Bednarz - Madison WI, US
Peter Carlson - Madison WI, US
International Classification:
A61K 51/04
C07K 16/30
A61K 38/20
A61K 9/00
Abstract:
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula:wherein Rcomprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and Ris —N(CH).

Radiohalogenated Agents For In Situ Immune Modulated Cancer Vaccination

View page
US Patent:
20180015154, Jan 18, 2018
Filed:
Jul 18, 2017
Appl. No.:
15/652400
Inventors:
- Madison WI, US
Paul M. Sondel - Madison WI, US
Anatoly Pinchuk - Fitchburg WI, US
Zachary Morris - Madison WI, US
Mario Otto - Fitchburg WI, US
Bryan Bednarz - Madison WI, US
International Classification:
A61K 39/00
A61K 51/04
Abstract:
A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula:wherein Ris a radioactive halogen isotope, n is 18 and Ris —N(CH).
Control profile
Paul M Sondel from Madison, WI Get Report